Spectral Medical (TSE:EDT) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Spectral Medical Inc. has announced significant progress in their Tigris trial for the treatment of septic shock, with 132 patients enrolled as of September 2024 and nearing the target enrollment for the study’s completion by year end. The company is advancing a novel therapeutic device, PMX, which has shown promise in treating septic shock and is seeking FDA approval.
For further insights into TSE:EDT stock, check out TipRanks’ Stock Analysis page.
